Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANEXSIA 7.5/650 vs EPCLUSA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
EPCLUSA is a fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an NS5A inhibitor. Sofosbuvir inhibits HCV RNA replication by acting as a chain terminator, while velpatasvir inhibits HCV replication by binding to NS5A and disrupting viral RNA replication and assembly.
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Treatment of chronic hepatitis C virus (HCV) infection in adults and pediatric patients 3 years and older,Treatment of genotype 1, 2, 3, 4, 5, or 6 HCV infection without cirrhosis or with compensated cirrhosis,Treatment of genotype 1, 2, 3, 4, 5, or 6 HCV infection with decompensated cirrhosis (in combination with ribavirin)
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
400 mg sofosbuvir / 100 mg velpatasvir orally once daily with or without food for 12 weeks.
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Sofosbuvir: 0.4 hr (parent), 27 hr (GS-331007); Velpatasvir: 15 hr. Clinical context: once-daily dosing achieves steady-state in ~1 week.
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Sofosbuvir is metabolized in the liver to its active metabolite (GS-461203) via cathepsin A (Cat A) and CES1, followed by phosphorylation. Velpatasvir is metabolized primarily by CYP2B6, CYP2C8, and CYP3A4.
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Sofosbuvir: 80% renal (as inactive metabolite GS-331007), 14% fecal; Velpatasvir: 94% fecal, 0.4% renal.
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
Sofosbuvir: 61-65% (human plasma proteins); Velpatasvir: >99.5% (mainly albumin, alpha-1 acid glycoprotein).
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Sofosbuvir: ~69 L (calculated as Vd/F); Velpatasvir: ~130 L (calculated as Vd/F). Not typically expressed per kg; indicates extensive tissue distribution.
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
Sofosbuvir: ~92% (oral, with food); Velpatasvir: ~25% (fasted), increased with high-fat meal (up to 2-fold).
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
No dose adjustment required for GFR ≥30 m L/min. Safety and efficacy not established for GFR <30 m L/min or hemodialysis; use with caution and consider alternative therapy.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
No dose adjustment for mild or moderate hepatic impairment (Child-Pugh A or B). Not recommended for use in severe hepatic impairment (Child-Pugh C) due to higher exposures of velpatasvir.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
For patients ≥6 years old or weighing ≥17 kg: fixed-dose combination (400 mg/100 mg) once daily with or without food, regardless of weight, for 12 weeks. Safety and efficacy not established for children <6 years or weighing <17 kg.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
No specific dose adjustment required based on age; use same dosing as younger adults, with monitoring for comorbidities and potential drug interactions.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
Risk of hepatitis B virus (HBV) reactivation in patients coinfected with HCV and HBV. Test all patients for evidence of current or prior HBV infection before initiating treatment. Monitor for HBV reactivation during and after treatment.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Risk of HBV reactivation in patients coinfected with HCV and HBV,Increased risk of bradycardia when used with amiodarone, especially in patients on beta-blockers or with cardiac comorbidities,Possible decreased therapeutic effect with strong P-glycoprotein (P-gp) inducers (e.g., rifampin, St. John's wort),Not recommended in patients with severe renal impairment (e GFR <30 m L/min) or end-stage renal disease requiring dialysis
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
Concomitant use with amiodarone (risk of symptomatic bradycardia),Concomitant use with strong P-glycoprotein (P-gp) inducers (e.g., rifampin, St. John's wort)
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
Take with or without food. No specific dietary restrictions. Avoid grapefruit juice? No interaction reported. Avoid alcohol as it can worsen liver disease.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
EPCLUSA (sofosbuvir/velpatasvir) is contraindicated in pregnancy due to the teratogenic risk associated with ribavirin (if used in combination). In the absence of ribavirin, there are no adequate human data; animal studies show no evidence of teratogenicity at clinically relevant exposures. However, due to the potential for ribavirin co-administration in some HCV regimens, pregnancy must be excluded before initiation and avoided during treatment and for 6 months after in females of childbearing potential.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
No data on the presence of sofosbuvir or velpatasvir in human milk, effects on the breastfed infant, or milk production. Because of the potential for adverse effects in the breastfed infant, breastfeeding is not recommended during treatment and for 6 months after the last dose, especially if ribavirin is co-administered. M/P ratio: unknown.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
No dose adjustment is recommended for EPCLUSA based on pregnancy alone. However, pharmacokinetic changes in pregnancy may alter drug exposure; therapeutic drug monitoring is not currently recommended. Safety and efficacy in pregnant women have not been established.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
EPCLUSA (sofosbuvir/velpatasvir) is a pangenotypic NS5B polymerase inhibitor and NS5A inhibitor combination for chronic HCV. For decompensated cirrhosis (Child-Pugh B/C), co-administer with ribavirin. Monitor for bradycardia when used with amiodarone; avoid co-administration if possible. Check for polymorphisms at baseline if HCV genotype 3 and cirrhosis (consider extending treatment). Assess renal function; not recommended if e GFR <30 m L/min/1.73m² unless on dialysis and benefit outweighs risk.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
Take one tablet (400 mg sofosbuvir/100 mg velpatasvir) orally once daily with or without food.,Complete the full course of treatment (12 weeks for most patients; 24 weeks for genotype 3 with cirrhosis or prior treatment failure).,Use of amiodarone with EPCLUSA can cause serious slowing of heartbeat (bradycardia). Inform your doctor if you take amiodarone.,Avoid taking rifampin, St. John's wort, or certain anticonvulsants (carbamazepine, phenytoin) as they reduce EPCLUSA effectiveness.,Report any symptoms of hepatitis B reactivation (fatigue, jaundice, dark urine) immediately.,If you have diabetes, monitor blood glucose closely as treatment may improve glucose control.,Use effective contraception during treatment and for 6 months after if using combined oral contraceptives containing ethinyl estradiol.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANEXSIA 7.5/650 vs EPCLUSA, answered by our medical review team.
ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. EPCLUSA is a Direct-Acting Antiviral (DAA) for Hepatitis C that works by EPCLUSA is a fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an NS5A inhibitor. Sofosbuvir inhibits HCV RNA replication by acting as a chain terminator, while velpatasvir inhibits HCV replication by binding to NS5A and disrupting viral RNA replication and assembly.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANEXSIA 7.5/650 and EPCLUSA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. The standard adult dose of EPCLUSA is: 400 mg sofosbuvir / 100 mg velpatasvir orally once daily with or without food for 12 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANEXSIA 7.5/650 and EPCLUSA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . EPCLUSA is classified as Category C. EPCLUSA (sofosbuvir/velpatasvir) is contraindicated in pregnancy due to the teratogenic risk associated with ribavirin (if used in combination). In the absence of ribavirin, there . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.